Study: NCT02802501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched-Placebo for Tafenoquine
Description: This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched-Placebo for Tafenoquine
Description: This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched-Placebo for Primaquine
Description: This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched-Placebo for Primaquine
Description: This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Description: This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Description: This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQP)
Description: This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing \<75 kg, 3 tablets will be administered per day. For subjects weighing \>=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT plus PQ (Rescue medication)
Description: Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT plus PQ (Rescue medication)
Description: Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT plus PQ (Rescue medication)
Description: Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PQ (End of study treatment)
Description: Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ (End of study treatment)
Description: Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (End of study treatment)
Description: Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.